Pharmacologic Management of Agitation in Patients with Dementia
- 22 January 2019
- journal article
- research article
- Published by Springer Nature in Current Geriatrics Reports
- Vol. 8 (1) , 1-11
Abstract
Purpose of Review Agitation is common among older adults with dementia; its origin may be multi-factorial, and it is often difficult to treat. In this paper, we summarize current knowledge and offer considerations on pharmacologic management of behavioral and psychological symptoms of dementia (BPSD). Recent Findings We reviewed human studies published from 2013 to 2018 evaluating pharmacologic management of BPSD manifestations including depressive symptoms, mania, psychosis, and other BPSD, as well as severe agitation without determination of underlying cause. After non-pharmacological management is exhausted, the choice of pharmacological options depends on patient comorbidities, specific BPSD presentation, and patient tolerance of medications. Summary Depending on manifestations of BPSD, low- to moderate-quality evidence supports the use of anti-depressants, anti-psychotics, or anti-epileptics in conjunction with cholinesterase inhibitors. The current evidence base needs to be augmented with future research that focuses on real-world medication use alongside head-to-head evaluation of medication effectiveness rather than comparison to placebo.Keywords
This publication has 62 references indexed in Scilit:
- Dying With Dementia: Symptoms, Treatment, and Quality of Life in the Last Week of LifeJournal of Pain and Symptom Management, 2014
- A randomized, controlled cross-over trial of dermally-applied lavender (Lavandula angustifolia) oil as a treatment of agitated behaviour in dementiaBMC Complementary and Alternative Medicine, 2013
- Efficacy and Tolerability of Risperidone, Yokukansan, and Fluvoxamine for the Treatment of Behavioral and Psychological Symptoms of DementiaJournal of Clinical Psychopharmacology, 2013
- A randomised controlled trial of the use of aromatherapy and hand massage to reduce disruptive behaviour in people with dementiaBMC Complementary and Alternative Medicine, 2013
- Alzheimer disease in the United States (2010–2050) estimated using the 2010 censusNeurology, 2013
- Use of Low-Dose Gabapentin for Aggressive Behavior in Vascular and Mixed Vascular/Alzheimer DementiaThe Journal of Neuropsychiatry and Clinical Neurosciences, 2013
- High‐Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical GuidelinesCNS Neuroscience & Therapeutics, 2013
- Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer DiseaseArchives of General Psychiatry, 2011
- Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's diseaseProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2009
- Cortical Cholinergic Function Is More Severely Affected in Parkinsonian Dementia Than in Alzheimer DiseaseArchives of Neurology, 2003